Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

InterbrandHealth

- PMLiVE

Pfizer begins phase 2/3 study of oral COVID-19 treatment in paediatric patients

The phase 2/3 trial involves around 140 patients under the age of 18

- PMLiVE

Ovarian Cancer Commitment announced to improve patient care

The coalition was announced by ENGAGe, ESGO and AstraZeneca in a call to improve ovarian cancer care

- PMLiVE

Novo Nordisk’s collaboration with MIT and BWH expanded

The new agreement means that the collaboration has been extended until 2026

- PMLiVE

Enhertu trial results show significant improvement for breast cancer patients

The treatment, jointly developed by AstraZenca and Daiichi Sankyo, was trialled in the pivotal DESTINY-Breast04 study

- PMLiVE

AZ’s Saphnelo receives EU approval for systemic lupus erythematosus

There are an estimated 250,000 people living with SLE in Europe and this is the first new drug to gain EU approval in over ten years

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

- PMLiVE

Pfizer’s Lorviqua receives EC approval for treatment of advanced lung cancer

The approval is based on the phase 3 CROWN trial comparing Lorviqua with Xalkori

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine

The clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster

- PMLiVE

AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients

The phase 3 trial results for patients diagnosed with first-line unresectable liver cancer showed a 31% survival rate after three years

- PMLiVE

AstraZeneca’s Enhertu receives FDA grant for priority review

The approval is based on results from the DESTINY-Breast03 trial which showed a significant risk reduction of unresectable or metastatic HER-2 positive breast cancer progression

- PMLiVE

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

The FDA based its approval on results from a clinical trial programme involving over 1,600 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links